Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1081 to 1091 of 1091 entries
Sorted by: Best Match Show Resources per page
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.

JAMA oncology

Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, Choueiri TK.
PMID: 34673916
JAMA Oncol. 2021 Dec 01;7(12):1815-1823. doi: 10.1001/jamaoncol.2021.4544.

IMPORTANCE: Patients with brain metastases from renal cell carcinoma (RCC) have been underrepresented in clinical trials, and effective systemic therapy is lacking. Cabozantinib shows robust clinical activity in metastatic RCC, but its effect on brain metastases remains unclear.OBJECTIVE: To...

Cite
Hirsch L, Martinez Chanza N, Farah S, et al. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncol. 2021;7(12):1815-1823doi: 10.1001/jamaoncol.2021.4544.
Hirsch, L., Martinez Chanza, N., Farah, S., Xie, W., Flippot, R., Braun, D. A., Rathi, N., Thouvenin, J., Collier, K. A., Seront, E., de Velasco, G., Dzimitrowicz, H., Beuselinck, B., Xu, W., Bowman, I. A., Lam, E. T., Abuqayas, B., Bilen, M. A., Varkaris, A., Zakharia, Y., Harrison, M. R., Mortazavi, A., Barthélémy, P., Agarwal, N., McKay, R. R., Brastianos, P. K., Krajewski, K. M., Albigès, L., Harshman, L. C., & Choueiri, T. K. (2021). Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA oncology, 7(12), 1815-1823. https://doi.org/10.1001/jamaoncol.2021.4544
Hirsch, Laure, et al. "Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma." JAMA oncology vol. 7,12 (2021): 1815-1823. doi: https://doi.org/10.1001/jamaoncol.2021.4544
Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, Choueiri TK. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncol. 2021 Dec 01;7(12):1815-1823. doi: 10.1001/jamaoncol.2021.4544. PMID: 34673916; PMCID: PMC8532040.
Copy Download .nbib Format: NLM
Say Hi.

JAMA oncology

Zhang E.
PMID: 34647968
JAMA Oncol. 2021 Dec 01;7(12):1907. doi: 10.1001/jamaoncol.2021.4315.

No abstract available.

Cite
Zhang E. Say Hi. JAMA Oncol. 2021;7(12):1907doi: 10.1001/jamaoncol.2021.4315.
Zhang, E. (2021). Say Hi. JAMA oncology, 7(12), 1907. https://doi.org/10.1001/jamaoncol.2021.4315
Zhang, Ellen. "Say Hi." JAMA oncology vol. 7,12 (2021): 1907. doi: https://doi.org/10.1001/jamaoncol.2021.4315
Zhang E. Say Hi. JAMA Oncol. 2021 Dec 01;7(12):1907. doi: 10.1001/jamaoncol.2021.4315. PMID: 34647968.
Copy Download .nbib Format: NLM
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.

JAMA oncology

Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JC, Riely GJ, Mekhail T, Nguyen D, Garcia Campelo MR, Felip E, Vincent S, Jin S, Griffin C, Bunn V, Lin J, Lin HM, Mehta M, Jänne PA.
PMID: 34647988
JAMA Oncol. 2021 Dec 01;7(12):e214761. doi: 10.1001/jamaoncol.2021.4761. Epub 2021 Dec 16.

IMPORTANCE: Metastatic non-small cell lung cancer (mNSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations is associated with a poor prognosis. Mobocertinib is an oral tyrosine kinase inhibitor designed to selectively target EGFRex20ins mutations.OBJECTIVE: To evaluate treatment outcomes and safety...

Cite
Zhou C, Ramalingam SS, Kim TM, et al. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol. 2021;7(12):e214761doi: 10.1001/jamaoncol.2021.4761.
Zhou, C., Ramalingam, S. S., Kim, T. M., Kim, S. W., Yang, J. C., Riely, G. J., Mekhail, T., Nguyen, D., Garcia Campelo, M. R., Felip, E., Vincent, S., Jin, S., Griffin, C., Bunn, V., Lin, J., Lin, H. M., Mehta, M., & Jänne, P. A. (2021). Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA oncology, 7(12), e214761. https://doi.org/10.1001/jamaoncol.2021.4761
Zhou, Caicun, et al. "Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial." JAMA oncology vol. 7,12 (2021): e214761. doi: https://doi.org/10.1001/jamaoncol.2021.4761
Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JC, Riely GJ, Mekhail T, Nguyen D, Garcia Campelo MR, Felip E, Vincent S, Jin S, Griffin C, Bunn V, Lin J, Lin HM, Mehta M, Jänne PA. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol. 2021 Dec 01;7(12):e214761. doi: 10.1001/jamaoncol.2021.4761. Epub 2021 Dec 16. PMID: 34647988; PMCID: PMC8517885.
Copy Download .nbib Format: NLM
American College of Surgeons Efforts in Support of Value-Based Metrics.

JAMA oncology

Nelson H, Ko CY, Hoyt DB.
PMID: 33300947
JAMA Oncol. 2021 Feb 01;7(2):307-308. doi: 10.1001/jamaoncol.2020.6462.

No abstract available.

Cite
Nelson H, Ko CY, Hoyt DB. American College of Surgeons Efforts in Support of Value-Based Metrics. JAMA Oncol. 2021;7(2):307-308doi: 10.1001/jamaoncol.2020.6462.
Nelson, H., Ko, C. Y., & Hoyt, D. B. (2021). American College of Surgeons Efforts in Support of Value-Based Metrics. JAMA oncology, 7(2), 307-308. https://doi.org/10.1001/jamaoncol.2020.6462
Nelson, Heidi, et al. "American College of Surgeons Efforts in Support of Value-Based Metrics." JAMA oncology vol. 7,2 (2021): 307-308. doi: https://doi.org/10.1001/jamaoncol.2020.6462
Nelson H, Ko CY, Hoyt DB. American College of Surgeons Efforts in Support of Value-Based Metrics. JAMA Oncol. 2021 Feb 01;7(2):307-308. doi: 10.1001/jamaoncol.2020.6462. PMID: 33300947.
Copy Download .nbib Format: NLM
Data Errors in the Table and Results.

JAMA oncology

[No authors listed]
PMID: 33300961
JAMA Oncol. 2021 Feb 01;7(2):312. doi: 10.1001/jamaoncol.2020.7104.

No abstract available.

Cite
Data Errors in the Table and Results. JAMA Oncol. 2021;7(2):312doi: 10.1001/jamaoncol.2020.7104.
(2021). Data Errors in the Table and Results. JAMA oncology, 7(2), 312. https://doi.org/10.1001/jamaoncol.2020.7104
"Data Errors in the Table and Results." JAMA oncology vol. 7,2 (2021): 312. doi: https://doi.org/10.1001/jamaoncol.2020.7104
Data Errors in the Table and Results. JAMA Oncol. 2021 Feb 01;7(2):312. doi: 10.1001/jamaoncol.2020.7104. PMID: 33300961; PMCID: PMC7729571.
Copy Download .nbib Format: NLM
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.

JAMA oncology

Schmoll HJ, Lindner LH, Reichardt P, Heißner K, Kopp HG, Kessler T, Mayer-Steinacker R, Rüssel J, Egerer G, Crysandt M, Kasper B, Niederwieser D, Kunitz A, Eigendorff E, Petersen I, Steighardt J, Cygon F, Meinert F, Stein A.
PMID: 33355646
JAMA Oncol. 2021 Feb 01;7(2):255-262. doi: 10.1001/jamaoncol.2020.6564.

IMPORTANCE: Pazopanib and gemcitabine have shown good tolerability, albeit modest single-agent activity in pretreated soft tissue sarcoma. A combined regimen to improve outcomes is required.OBJECTIVE: To determine the efficacy of gemcitabine and pazopanib compared with pazopanib alone.DESIGN, SETTING, AND...

Cite
Schmoll HJ, Lindner LH, Reichardt P, et al. Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(2):255-262doi: 10.1001/jamaoncol.2020.6564.
Schmoll, H. J., Lindner, L. H., Reichardt, P., Heißner, K., Kopp, H. G., Kessler, T., Mayer-Steinacker, R., Rüssel, J., Egerer, G., Crysandt, M., Kasper, B., Niederwieser, D., Kunitz, A., Eigendorff, E., Petersen, I., Steighardt, J., Cygon, F., Meinert, F., & Stein, A. (2021). Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. JAMA oncology, 7(2), 255-262. https://doi.org/10.1001/jamaoncol.2020.6564
Schmoll, Hans-Joachim, et al. "Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial." JAMA oncology vol. 7,2 (2021): 255-262. doi: https://doi.org/10.1001/jamaoncol.2020.6564
Schmoll HJ, Lindner LH, Reichardt P, Heißner K, Kopp HG, Kessler T, Mayer-Steinacker R, Rüssel J, Egerer G, Crysandt M, Kasper B, Niederwieser D, Kunitz A, Eigendorff E, Petersen I, Steighardt J, Cygon F, Meinert F, Stein A. Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Feb 01;7(2):255-262. doi: 10.1001/jamaoncol.2020.6564. PMID: 33355646; PMCID: PMC7758834.
Copy Download .nbib Format: NLM
Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.

JAMA oncology

Kratz CP, Freycon C, Maxwell KN, Nichols KE, Schiffman JD, Evans DG, Achatz MI, Savage SA, Weitzel JN, Garber JE, Hainaut P, Malkin D.
PMID: 34709361
JAMA Oncol. 2021 Dec 01;7(12):1800-1805. doi: 10.1001/jamaoncol.2021.4398.

IMPORTANCE: Li-Fraumeni syndrome is a cancer predisposition syndrome that is associated with a high, lifelong risk of a broad spectrum of cancers that is caused by pathogenic TP53 germline variants. A definition that reflects the broad phenotypic spectrum that...

Cite
Kratz CP, Freycon C, Maxwell KN, et al. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis. JAMA Oncol. 2021;7(12):1800-1805doi: 10.1001/jamaoncol.2021.4398.
Kratz, C. P., Freycon, C., Maxwell, K. N., Nichols, K. E., Schiffman, J. D., Evans, D. G., Achatz, M. I., Savage, S. A., Weitzel, J. N., Garber, J. E., Hainaut, P., & Malkin, D. (2021). Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis. JAMA oncology, 7(12), 1800-1805. https://doi.org/10.1001/jamaoncol.2021.4398
Kratz, Christian P, et al. "Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis." JAMA oncology vol. 7,12 (2021): 1800-1805. doi: https://doi.org/10.1001/jamaoncol.2021.4398
Kratz CP, Freycon C, Maxwell KN, Nichols KE, Schiffman JD, Evans DG, Achatz MI, Savage SA, Weitzel JN, Garber JE, Hainaut P, Malkin D. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis. JAMA Oncol. 2021 Dec 01;7(12):1800-1805. doi: 10.1001/jamaoncol.2021.4398. PMID: 34709361; PMCID: PMC8554692.
Copy Download .nbib Format: NLM
Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease.

JAMA oncology

Ollila TA, Lu S, Masel R, Zayac A, Paiva K, Rogers RD, Olszewski AJ.
PMID: 34379085
JAMA Oncol. 2021 Nov 01;7(11):1714-1716. doi: 10.1001/jamaoncol.2021.4381.

No abstract available.

Cite
Ollila TA, Lu S, Masel R, et al. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease. JAMA Oncol. 2021;7(11):1714-1716doi: 10.1001/jamaoncol.2021.4381.
Ollila, T. A., Lu, S., Masel, R., Zayac, A., Paiva, K., Rogers, R. D., & Olszewski, A. J. (2021). Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease. JAMA oncology, 7(11), 1714-1716. https://doi.org/10.1001/jamaoncol.2021.4381
Ollila, Thomas A, et al. "Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease." JAMA oncology vol. 7,11 (2021): 1714-1716. doi: https://doi.org/10.1001/jamaoncol.2021.4381
Ollila TA, Lu S, Masel R, Zayac A, Paiva K, Rogers RD, Olszewski AJ. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease. JAMA Oncol. 2021 Nov 01;7(11):1714-1716. doi: 10.1001/jamaoncol.2021.4381. PMID: 34379085; PMCID: PMC8358793.
Copy Download .nbib Format: NLM
Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.

JAMA oncology

Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X.
PMID: 34762100
JAMA Oncol. 2021 Nov 11; doi: 10.1001/jamaoncol.2021.5143. Epub 2021 Nov 11.

IMPORTANCE: In April 2017, the US Preventive Services Task Force (USPSTF) published a draft guideline that reversed its 2012 guidance advising against prostate-specific antigen (PSA)-based screening for prostate cancer in all men (grade D), instead endorsing individual decision-making for...

Cite
Leapman MS, Wang R, Park H, et al. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncol. 2021;doi: 10.1001/jamaoncol.2021.5143.
Leapman, M. S., Wang, R., Park, H., Yu, J. B., Sprenkle, P. C., Cooperberg, M. R., Gross, C. P., & Ma, X. (2021). Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA oncology, . https://doi.org/10.1001/jamaoncol.2021.5143
Leapman, Michael S, et al. "Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening." JAMA oncology vol. (2021). doi: https://doi.org/10.1001/jamaoncol.2021.5143
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncol. 2021 Nov 11; doi: 10.1001/jamaoncol.2021.5143. Epub 2021 Nov 11. PMID: 34762100; PMCID: PMC8587214.
Copy Download .nbib Format: NLM
Clinical Trial Enrollment of Racial, Ethnic, and Underrepresented Groups-Leveraging a Digital Infrastructure.

JAMA oncology

Culbert M, Oladeru OT.
PMID: 34351362
JAMA Oncol. 2021 Oct 01;7(10):1447-1448. doi: 10.1001/jamaoncol.2021.2680.

No abstract available.

Cite
Culbert M, Oladeru OT. Clinical Trial Enrollment of Racial, Ethnic, and Underrepresented Groups-Leveraging a Digital Infrastructure. JAMA Oncol. 2021;7(10):1447-1448doi: 10.1001/jamaoncol.2021.2680.
Culbert, M., & Oladeru, O. T. (2021). Clinical Trial Enrollment of Racial, Ethnic, and Underrepresented Groups-Leveraging a Digital Infrastructure. JAMA oncology, 7(10), 1447-1448. https://doi.org/10.1001/jamaoncol.2021.2680
Culbert, Matthew, and Oladeru, Oluwadamilola T. "Clinical Trial Enrollment of Racial, Ethnic, and Underrepresented Groups-Leveraging a Digital Infrastructure." JAMA oncology vol. 7,10 (2021): 1447-1448. doi: https://doi.org/10.1001/jamaoncol.2021.2680
Culbert M, Oladeru OT. Clinical Trial Enrollment of Racial, Ethnic, and Underrepresented Groups-Leveraging a Digital Infrastructure. JAMA Oncol. 2021 Oct 01;7(10):1447-1448. doi: 10.1001/jamaoncol.2021.2680. PMID: 34351362.
Copy Download .nbib Format: NLM
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.

JAMA oncology

Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D, Gill S, Higgs B, Wagenfuehr K, Montgomery R, Awad R, Chesson B, Eade T, Wong W, Sasso G, De Abreu Lourenco R, Kron T, Ball D, Neeson P.
PMID: 34455431
JAMA Oncol. 2021 Oct 01;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939.

IMPORTANCE: Evidence is lacking from randomized clinical trials to guide the optimal approach for stereotactic ablative body radiotherapy (SABR) in patients with pulmonary oligometastases.OBJECTIVE: To assess whether single-fraction or multifraction SABR is more effective for the treatment of patients...

Cite
Siva S, Bressel M, Mai T, et al. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(10):1476-1485doi: 10.1001/jamaoncol.2021.2939.
Siva, S., Bressel, M., Mai, T., Le, H., Vinod, S., de Silva, H., Macdonald, S., Skala, M., Hardcastle, N., Rezo, A., Pryor, D., Gill, S., Higgs, B., Wagenfuehr, K., Montgomery, R., Awad, R., Chesson, B., Eade, T., Wong, W., Sasso, G., De Abreu Lourenco, R., Kron, T., Ball, D., Neeson, P. (2021). Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA oncology, 7(10), 1476-1485. https://doi.org/10.1001/jamaoncol.2021.2939
Siva, Shankar, et al. "Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial." JAMA oncology vol. 7,10 (2021): 1476-1485. doi: https://doi.org/10.1001/jamaoncol.2021.2939
Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D, Gill S, Higgs B, Wagenfuehr K, Montgomery R, Awad R, Chesson B, Eade T, Wong W, Sasso G, De Abreu Lourenco R, Kron T, Ball D, Neeson P. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Oct 01;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939. PMID: 34455431; PMCID: PMC8404145.
Copy Download .nbib Format: NLM
Showing 1081 to 1091 of 1091 entries